RCKT - Biotech Bonanza: 2021 Outlook In A Post-Pandemic Year

• 2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market.
• Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine trials.
• A low interest rate macro environment, scientific advances, and M&A to boost biotech valuations.
• Regulatory noise around drug-pricing to increase in the second-half, though no meaningful change to occur this year.
• Fundamentals and technical appear aligned for 2021 to be a strong year for biotechs, with a couple of potential catalysts expected in January.

For further details see: